Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Page 1
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes.
Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P; Alzheimer's Disease Genetics Consortium; Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD. Jun G, et al. Arch Neurol. 2010 Dec;67(12):1473-84. doi: 10.1001/archneurol.2010.201. Epub 2010 Aug 9. Arch Neurol. 2010. PMID: 20697030 Free PMC article.
Models with the main SNP effect, presence or absence of APOE epsilon4, and an interaction term showed significant interaction between presence or absence of APOE epsilon4 and PICALM. ...
Models with the main SNP effect, presence or absence of APOE epsilon4, and an interaction term showed significant interaction between …
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.
Serrano-Pozo A, Vega GL, Lütjohann D, Locascio JJ, Tennis MK, Deng A, Atri A, Hyman BT, Irizarry MC, Growdon JH. Serrano-Pozo A, et al. Among authors: growdon jh. Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):220-6. doi: 10.1097/WAD.0b013e3181d61fea. Alzheimer Dis Assoc Disord. 2010. PMID: 20473136 Free PMC article. Clinical Trial.
Our findings indicate that simvastatin treatment can affect brain cholesterol metabolism within 12 weeks, but did not alter molecular indices of AD pathology during this short-term treatment....
Our findings indicate that simvastatin treatment can affect brain cholesterol metabolism within 12 weeks, but did not alter molecular indice …
Long-term course and effectiveness of combination therapy in Alzheimer disease.
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Atri A, et al. Among authors: growdon jh. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):209-21. doi: 10.1097/WAD.0b013e31816653bc. Alzheimer Dis Assoc Disord. 2008. PMID: 18580597 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the real-world clinical effectiveness and long-term clinical trajectory in patients with Alzheimer disease (AD) treated with combination (COMBO) therapy consisting of cholinesterase-inhibitor (CI) plus memantine (MEM) versus CI alone versus no treatme …
OBJECTIVE: To compare the real-world clinical effectiveness and long-term clinical trajectory in patients with Alzheimer disease (AD) …
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK; DLB/PDD Working Group. Lippa CF, et al. Among authors: growdon jh. Neurology. 2007 Mar 13;68(11):812-9. doi: 10.1212/01.wnl.0000256715.13907.d3. Neurology. 2007. PMID: 17353469 Review.
The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use of these three clinical terms, and to encourage efforts at drug discovery that target the mechanisms of neurodegeneration shared by these d …
The authors agreed to endorse "Lewy body disorders" as the umbrella term for PD, PDD, and DLB, to promote the continued practical use …
Working memory in mild Alzheimer's disease and early Parkinson's disease.
Kensinger EA, Shearer DK, Locascio JJ, Growdon JH, Corkin S. Kensinger EA, et al. Among authors: growdon jh. Neuropsychology. 2003 Apr;17(2):230-9. doi: 10.1037/0894-4105.17.2.230. Neuropsychology. 2003. PMID: 12803428 Clinical Trial.
To address this issue, the authors compared the performance of 22 patients with mild AD, 20 patients with early PD and without dementia, and 112 control participants on tests of inhibition, short-term memory, and 2 commonly administered tests of WM. The results suggest tha …
To address this issue, the authors compared the performance of 22 patients with mild AD, 20 patients with early PD and without dementia, and …
The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.
Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. Nitsch RM, et al. Among authors: growdon jh. Ann Neurol. 2000 Dec;48(6):913-8. Ann Neurol. 2000. PMID: 11117548
If this effect also occurs in brain, M1 agonists may have long-term therapeutic benefits by lowering amyloid in AD....
If this effect also occurs in brain, M1 agonists may have long-term therapeutic benefits by lowering amyloid in AD....
Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Growdon JH, et al. Neurology. 1998 May;50(5):1327-31. doi: 10.1212/wnl.50.5.1327. Neurology. 1998. PMID: 9595982
OBJECTIVE: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psychiatric aspects of Parkinson's disease (PD). ...
OBJECTIVE: The objective of the study was to determine the effects of short-term levodopa administration on motor, cognitive, and psy …
Muscarinic agonists in Alzheimer's disease.
Growdon JH. Growdon JH. Life Sci. 1997;60(13-14):993-8. doi: 10.1016/s0024-3205(97)00039-8. Life Sci. 1997. PMID: 9121366
As therapeutic agents, M1 agonists in the short-term may palliate symptoms of AD and improve memory function. In the long-term, M1 agonists have the potential to modify the underlying pathophysiology of AD, and thereby prevent or retard the course of dementia....
As therapeutic agents, M1 agonists in the short-term may palliate symptoms of AD and improve memory function. In the long-term …
Priming in perceptual identification of pseudowords is normal in Alzheimer's disease.
Keane MM, Gabrieli JD, Growdon JH, Corkin S. Keane MM, et al. Among authors: growdon jh. Neuropsychologia. 1994 Mar;32(3):343-56. doi: 10.1016/0028-3932(94)90136-8. Neuropsychologia. 1994. PMID: 8202228 Free article.
These results extend the boundaries of intact repetition priming in AD, demonstrating that such priming is not limited to stimuli that are pre-morbidly represented in long-term knowledge. Preserved repetition priming in AD may reflect the operation of perceptual processes …
These results extend the boundaries of intact repetition priming in AD, demonstrating that such priming is not limited to stimuli that are p …
13 results